Product
BMF-500
1 clinical trial
3 indications
Indication
Acute Myeloid LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
Acute Mixed-Phenotype LeukemiaClinical trial
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute LeukemiaStatus: Recruiting, Estimated PCD: 2025-07-31